Background: Auditory complications are an adverse event of childhood cancer treatment, especially common in children treated with platinum chemotherapy or cranial radiation. Variation between diagnostic childhood cancer groups has rarely been studied, and we do not know if the burden of auditory complications has changed over the last decades. 
INTRODUCTION
Ototoxicity, leading to auditory complications like hearing loss or tinnitus, is an adverse event of childhood cancer treatment, especially Abbreviations: BMT, bone marrow transplantation; CI, confidence interval; CNS, central nervous system; CSF-shunt, cerebrospinal fluid shunt; Gy, gray; HR, hazard ratio; ICCC-3, International Classification of Childhood Cancer, Third edition; IQR, interquartile range; OR, odds ratio; SCCR, Swiss Childhood Cancer Registry; SCCSS, Swiss Childhood Cancer Survivor Study common in children treated with platinum chemotherapy or cranial radiation. 1, 2 Since its introduction in the 1980s, platinum chemotherapy has been widely used to treat many kinds of childhood cancer.
Platinum compounds can damage the hair cells, the spiral ganglion neurons, and the stria vascularis in the cochlear duct of the inner ear, and may cause sensorineural hearing loss or tinnitus in both ears. [3] [4] [5] Radiation can damage any of the auditory structures, causing sensorineural, conductive or mixed hearing loss or tinnitus. 6, 7 The treatment can affect one or both ears, depending on the area radiated. Auditory complications cause functional limitations, affect speech development, and impair neurocognitive functioning, educational performance, and quality of life. [8] [9] [10] [11] A large U.S. study found an increased risk of auditory complications in a diverse cohort of survivors, but included only survivors from early diagnosis years (1970) (1971) (1972) (1973) (1974) (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) . 12 Since 1986 ototoxicity from platinum chemotherapy may have increased as cisplatin came into common use. Later, cisplatin has been increasingly replaced by the less ototoxic carboplatin, and radiation techniques have improved and deliver lower radiation doses to the cochlea. 13, 14 It remains unclear if and how more current treatment regimens have shifted the burden of long-term auditory complications in survivors of all diagnostic groups.
Recent estimates of prevalence and incidence of auditory complications vary widely, 1 and studies are hard to compare. Studies on longterm outcomes have tended to focus on selected diagnostic groups, including brain tumor, 15, 16 neuroblastoma, 8 hepatoblastoma, 17 or nasopharyngeal carcinoma, 18 or included a selected treatment group. 19 The overall burden of auditory complications and variations between diagnostic groups have not been well described.
We addressed these open questions by investigating the prevalence of self-reported hearing loss and tinnitus in survivors of all diagnostic childhood cancer groups, among survivors diagnosed between 1976 and 2005, and compared those results to that of siblings. We also assessed the effects of cancer treatment on hearing loss, and if the incidence of hearing loss has changed over time.
METHODS

The Swiss Childhood Cancer Survivor Study
The Swiss Childhood Cancer Survivor Study (SCCSS) is a populationbased, long-term follow-up study of all patients registered in the Swiss Childhood Cancer Registry (SCCR), who were diagnosed 1976-2005 at age 16 years or less, and who have survived 5 years or more after initial diagnosis of cancer. 20 The SCCR is a population-based registry and includes all children and adolescents in Switzerland who were diagnosed with leukemia, lymphoma, central nervous system (CNS) tumors, malignant solid tumors, or Langerhans cell histiocytosis before they turned 21. 21 From 2007 to 2013, we traced addresses and sent a questionnaire to all survivors. Nonresponders were mailed a second copy of the questionnaire 4-6 weeks after the first. If they again did not respond, we contacted them by phone. We asked survivors for consent to contact their siblings, who made up the comparison group. If survivors agreed, we sent the same questionnaire to siblings, minus the cancerrelated questions. Siblings who did not respond to the first questionnaire received a second copy 4-6 weeks later, but we did not contact them by phone. Details of the study design have been published elsewhere. 20 The Ethics Committee of Canton Bern granted ethical approval to the SCCR and SCCSS.
Explanatory variables and outcomes
Explanatory variables
We obtained sociodemographic, cancer-, and treatment-related information from the SCCR, which includes detailed medical information on the tumor and therapy. Missing treatment information was complemented by data extracted from hospital records. We extracted the following variables from the SCCR: sex, cancer diagnosis, year and age of cancer diagnosis, age at survey, chemotherapy (yes/no), clinical study participation (yes/no), treatment protocol, radiotherapy (yes/no, area, dose), surgery (yes/no, area, type), and bone marrow transplant (BMT) (yes/no). Cancer diagnosis was classified according to the International Classification of Childhood Cancer, third edition (ICCC-3). 22 We determined whether patients were treated with cisplatin and carboplatin (yes/no) from SCCR data on clinical study participation and treatment protocols. We summarized radiation doses to the head and categorized cranial radiation into four categories: no cranial radiation, 
Auditory outcomes
The SCCSS questionnaire asked survivors and siblings about their auditory health. Participants were asked if a doctor had told them they had auditory complications ( Supplementary Fig. S3 ) and then asked to describe the severity and laterality (unilateral/bilateral) of the auditory complication. We created a binary variable (yes/no) for hearing loss and tinnitus; missing information on auditory complications was coded as no (hearing loss, 3% in survivors and siblings; tinnitus, 2% in survivors and 1% in siblings). We categorized severity of hearing loss as mild hearing loss, moderate hearing loss, or deafness. We asked responders who had auditory complications and were older than 15 years at the time of survey (n = 1,606) for the year of first occurrence of hearing loss. Survivors less than or 15 years old were not included in our analysis of cumulative incidence of hearing loss.
Statistical analysis
First, we used chi-square tests to compare prevalence of self-reported hearing loss and tinnitus in survivors and siblings, and described laterality and severity of hearing loss. We stratified survivors by diagnostic group and compared prevalence of hearing loss in survivors and siblings.
Second, we performed uni-and multivariable logistic regressions only on survivor data to identify the effect of cancer-related treatment (use of platinum compounds, cranial radiation, brain surgery, CSF-shunt, and BMT) on hearing loss after cancer diagnosis. We included all treatment-related variables and adjusted for sex and age at cancer diagnosis in the multivariable regression model according to the literature. 9, 23 We computed likelihood ratio tests to calculate global P values.
Third, we used the Kaplan-Meier method to estimate cumulative incidence curves and calculated cumulative incidence for hearing loss 15 years after cancer diagnosis, stratified by treatment group. We assessed time trends in cumulative incidence of hearing loss after cancer diagnosis, based on the period in which the survivor was diagnosed. We estimated incidence curves and hazard ratios (HRs) for survivors overall and separately for each treatment group and stratified by period of cancer diagnosis. We used inverse probability weights to adjust the incidence curves for diagnostic groups 24 and log-rank tests to test for equivalence of incidence curves.
To increase comparability of survivors and siblings with respect to sex and age at survey, we standardized the siblings to the survivors by the above-mentioned characteristics (our method is described in previous publications). 25 We imputed age at time of occurrence of hearing loss if a survivor reported hearing loss but not the year of first occurrence (n = 43). We used observed values (sex, age at cancer diagnosis, cancer diagnosis, cranial radiotherapy, platinum chemotherapy) in the imputation model to generate the missing age. 26 We used the software package Stata (Version 13, Stata Corporation, Austin, Texas) for all analyses, and the missforest package for R
(R Foundation for Statistical
Computing, Vienna, Austria) for multiple imputation.
RESULTS
Characteristics of study population
We contacted 2,884 survivors and 1,526 siblings ( Supplementary Fig.   S1 ). Questionnaires were returned by 2,061 survivors (response rate 71%) and 864 siblings (response rate 57%).
Of the participating survivors, 54% were male; median (interquartile [IQR]) age at survey was 21 years (6-46) ( Table 1 ). The most common diagnosis among survivors was leukemia (36%), followed by lymphoma (16%) and CNS tumor (14%). Median (IQR) age at cancer diagnosis was 5 years (0-15); median (IQR) time since cancer diagnosis was 15 years (5-38). Of survivors who had received chemotherapy, 6% had been treated with carboplatin, 7% with cisplatin, and 4% with both. Of those who received radiation, 54% had received cranial radiation. Of those who had had surgery, 25% had brain surgery and 7% had a CSF-shunt. Five percent of survivors had received a BMT. Responders were older at survey (P < 0.001), more often female (P < 0.001), more often diagnosed with leukemia or renal tumor (P = 0.007), and had surgery less often than nonresponders (P = 0.039) ( Table 1) .
Prevalence of hearing loss and tinnitus in survivors and siblings
Survivors reported hearing loss more often than siblings did (10 vs. 3%; P < 0.001) (Fig. 1 ). Hearing loss was usually mild (7% in survivors vs. 3%
in siblings) and rarely moderate (2% in survivors vs. 0% in siblings) or severe (1% in survivors vs. 0.2% in siblings; P < 0.001) ( 
Treatment-related risk factors for hearing loss after cancer diagnosis
In the univariable regression, survivors treated with carboplatin (odds ratio [OR] 3.5), cisplatin (OR 11.0), or both (OR 12.7) more often developed hearing loss after cancer diagnosis than those who were not exposed to platinum compounds (P < 0.001) ( Table 3) . Survivors who had received moderate or high doses of cranial radiation were more likely to report hearing loss after cancer diagnosis (30-49 Gy: OR 2.7; ≥50 Gy: OR 5.5) than those who had not been cranially irradiated (P < 0.001). Survivors who had had brain surgery (OR 4.1, P < 0.001),
CSF-shunt (OR 3.6, P < 0.001), or BMT (OR 2.3, P = 0.005) were also more likely to develop hearing loss.
In the multivariable regression, survivors with the following treatments were more likely to develop hearing loss: platinum compounds (carboplatin: OR 2.4; cisplatin: OR 9.4; both combined: OR 8.6; P < 0.001), cranial radiation doses higher than 29 Gy (30-49 Gy: OR 1.7;
≥50 Gy: OR 2.1; P = 0.016), brain surgery (OR 2.2; P = 0.001), and BMT (OR 2.1; P = 0.023) ( Table 3 and Supplementary Fig. S2 ).
Cumulative incidence and onset of hearing loss by treatment group
Cumulative incidence of hearing loss 15 years after cancer diagnosis differed between treatment groups. Survivors treated with both platinum compounds and cranial radiation had the highest cumulative incidence (63%; 95% confidence interval [CI] 40-98%), followed by those treated with only platinum compounds (30%; 95% CI 21-42%), only cranial radiation (9%; 95% CI 6-13%), and those who had had neither of these therapies (5%; 95% CI 4-7%; overall P < 0.001) (Fig. 2) .
In groups treated with platinum compounds, cumulative incidence began to increase in the first year after cancer diagnosis. Survivors treated only with platinum compounds developed hearing loss no later than 7 years after diagnosis, but in survivors with cranial radiation or both, cranial radiation and platinum compounds, cumulative incidence continued to increase until 17 years after diagnosis. 
TA B L E 1 Characteristics of childhood cancer survivors and siblings
Cumulative incidence of hearing loss by period of cancer diagnosis
Cumulative incidence differed between periods of cancer diagnosis (Fig. 3) . We first looked at all survivors together (panel A). The risk of 
DISCUSSION
This comprehensive national survey of hearing loss after childhood cancer found that prevalence of self-reported hearing loss was significantly higher in childhood cancer survivors than in siblings and varied between diagnostic groups, with the highest prevalence in survivors of CNS tumors. Incidence of hearing loss increased significantly after platinum compounds were introduced in the 1980s, but tended We found a high prevalence of hearing loss (10%) among childhood cancer survivors. The U.S. Childhood Cancer Survivor Study found lower prevalence of self-reported hearing loss (5%) among survivors of childhood cancer than we did. 12 The discrepancy between the two studies may result from differences in study period and length of observation: The U.S. study did not include survivors diagnosed after 1986, when platinum compounds came into common use, while we included all survivors diagnosed up to 2005. Also, the U.S. study assessed prevalence of hearing loss up to 5 years after diagnosis only, while our mean follow-up time was 15 years. We have shown that cumulative incidence continues to increase well beyond 5 years from diagnosis particularly for those treated with cranial radiation.
TA B L E 2 Severity and laterality of self-reported hearing loss in survivors and siblings
When we looked at single diagnostic groups, we found that every fourth survivor of CNS tumor or neuroblastoma reported hearing loss, which is similar to the findings of Christopherson et al. 16 in survivors with CNS tumors (21%) and Gurney et al. 8 in survivors of neuroblastoma (31%).
Prevalence of tinnitus was relatively low in our study, in both survivors (4%) and siblings (5%). The U.S. study found a higher 5-year prevalence in survivors (6%), and differences to siblings (1%). 12 We identified platinum compounds, cranial radiation at doses 30 Gy or higher, brain surgery, and BMT as risk factors for hearing loss. A large body of literature shows the effect of cumulative dose of platinum compounds on hearing loss. 1 Several studies have reported a dose-dependent relationship between cochlear radiation and hearing loss, with a threshold dose in the range of 35-45 Gy. 6, 27 Survivors with BMT are at notably increased risk of hearing loss, 19, 28 but BMT has no ototoxic effect and is a surrogate for accompanying pretreatments that include total body irradiation or myeloablative chemotherapy with high-dose platinum compounds. We found high prevalence of hearing loss in survivors who had had brain surgery. Brain surgery may lead to auditory complications when the tumor is located near auditory structures. 27, 29 We found no association between hearing loss and CSF-shunt, even though two U.S. studies in children with brain tumors found that rapid changes in intracranial pressure from hydrocephalus itself or from subsequent shunting affect cochlear physiology and can cause hearing loss. 27, 30 Our study might have underestimated the effect of CSF shunt, since we had no detailed information on changes in intracranial pressure.
We found the highest cumulative incidence of hearing loss 15 years postdiagnosis in survivors who had been treated with both platinum compounds and cranial radiation (63%). A U.S. study by Knight et al. 9 found that 80% of patients with medulloblastoma and osteosarcoma, who are often treated with both cranial radiation or platinum compounds developed hearing loss within 200 days after diagnosis. When we looked at time intervals between diagnosis and onset of hearing loss, we saw that auditory complications that followed treatment with platinum compounds always appeared within 7 years of diagnosis.
Onset of auditory complications after radiotherapy could occur much later (up to 17 years after diagnosis). Two U.S. studies reported similar time intervals between platinum administration and detection of hearing loss: 6-82 months in Qaddoumi et al. 31 and 12-98 months in Kolinsky et al. 32 The U.S. childhood cancer survivor study reported that survivors who had had cranial radiation developed hearing loss as late as 15 years after diagnosis. 12 We found no other study that compared cumulative incidence curves between different periods of cancer diagnosis because previous studies had investigated shorter time periods after cancer diagnosis (e.g., 1970-1986, 12,15 1974-1998, 19 1995-2008 23 ).
In our study, the incidence of hearing loss increased with the widespread introduction of platinum compounds from 1985 onward, but tended to decrease again for patients diagnosed in the last period, 1996-2005. The decrease in hearing loss after 1995 could be explained by more recent clinical protocols, which recommend to replace cisplatin with the less toxic carboplatin at the first sign of auditory complications. 33, 34 The incidence of hearing loss in survivors who had received only cranial radiation also tended to decrease after 1996, perhaps because modern protocols use new radiation techniques like three-dimensional conformal or intensity-modulated radiation therapy. 13, 14, 35 The decrease in incidence of hearing loss after 1996 could also be caused by the shorter follow-up time between diagnosis and questionnaire survey in the last period, as it is well known that hearing loss after cranial radiation may begin many years after treatment. We are currently contacting survivors with a second follow-up questionnaire. These data will then allow further investigation of this potential bias. The consistent results for survivors treated with both cranial radiation and platinum compounds might be explained by changes in treatment regimens for CNS tumor patients, who made up a large proportion of our participants. Until the end of the 1980s, these patients had been treated with radiotherapy instead of chemotherapy. When platinum compounds became available, treatment regimens changed: CNS tumor patients were prescribed both craniospinal radiation and platinum compounds. 16, 36 In the late 1990s, when it became obvious that cranial radiation caused neurocognitive effects, new protocols reduced radiation doses but intensified platinum chemotherapy. 37, 38 In summary, most patients diagnosed with CNS tumors, neuroblastomas, hepatic tumors, bone tumors, soft tissue sarcomas, and germ cell tumors receive ototoxic treatments like platinum compounds, cranial radiation, or brain surgery. These diagnostic groups are at high risk of hearing loss and should be closely monitored with audiological tests during, and for many years after cancer treatment. If auditory complications are detected early, physicians can counsel patients, offer them hearing aids, and perhaps prevent the progress of hearing loss and F I G U R E 2 Cumulative incidence of hearing loss since year of diagnosis, by treatment groups P, P value. Analysis is restricted to questionnaires answered by adolescents and adults (n = 1,606). Multiple imputation was used to impute missing values for year of onset of hearing loss in n = 43. P-value is calculated with log-rank test. Time of onset of hearing loss was reported in years.
TA B L E 3 Effect of treatment-related factors on hearing loss after cancer diagnosis
secondary effects like impaired speech development or neurocognitive functioning. 10, 11, 39 Our study has some limitations. First, numbers of survivors with auditory complications were relatively small in some diagnostic groups and we may have missed some effects because CIs were large. We used self-reported information on auditory complications, so complications could have been underreported, especially when hearing was affected only in the high frequencies and did not affect survivor's daily life, or when tinnitus after cancer treatment disappeared. However, an
Australian study suggests that self-reports have a reasonable sensitivity (78-100%) for detecting hearing loss when pure-tone audiometry was used as the gold standard. 40 Our study was strengthened by its large representative populationbased sample of childhood cancer survivors. We followed survivors over a long period of time, covered all diagnostic groups, and also included survivors who had been diagnosed in different time periods. Our study is the first to investigate the prevalence of auditory complications among all diagnostic groups of childhood cancer and to compare incidence between different periods of cancer diagnosis.
Few other studies investigated tinnitus in addition to hearing loss in long-term childhood cancer survivors.
F I G U R E 3 Cumulative incidence of hearing loss after cancer diagnosis based on treatment groups stratified by period of cancer diagnosis, adjusted for diagnostic group P, P value. Analysis is restricted to questionnaires answered by adolescents and adults (n = 1,606). Multiple imputation was used to impute missing values for year of onset of hearing loss in n = 43. Time of onset of hearing loss was reported in years. Global P-values are calculated with log-rank tests. * Since approval for cisplatin was in 1979 and for carboplatin in 1986 in Switzerland, the time period 1976-1985 was not computed. 
